Tumours stratified as hot, intermediate, or cold based on CD8+ T cell infiltration; identified biomarkers (HLA class I, CD8, DNMT3A) predictive of immune checkpoint inhibitor efficacy; biomarkers validated via multiplexed immunofluorescence and immunohistochemistry. The gene discussed is DNMT3A; the disease is neoplasm.